Deals In Depth: February 2015
AstraZeneca took on a large respiratory portfolio through a $700 million deal with Actavis; Pfizer improved biosimilar capabilities through its $17 billion takeover of Hospira. Follow-on public offerings dominated biopharma and device financing.
You may also be interested in...
Improvements in generating, purifying, and delivering RNA material, as well as addressing challenges with degradation by enzymes, have made the RNA class more attractive to drug developers.
The market for new company creation in the biopharma sector remains healthy and poised to continue fostering the establishment of start-ups, based on a new In Vivo study of the strong initial investments that pharma and biotech companies receive.
In conducting pharma market opportunity assessments, there are several best practices that exist and common mistakes to avoid. In Vivo shares expert learnings from Pharma Intelligence’s Custom Intelligence leaders.